Health  Mr. Speaker, the truth is that the government's failure of leadership and lack of vision is putting our cherished public health care system at great peril. The Conservatives have failed to address important challenges like the high cost of prescription drugs. They have unilaterally slashed funding, and they have taken no steps toward the next generation of health care, like taking action on pharmacare or home care.

Epilepsy  Mr. Speaker, I rise because it is Purple Day, a day that has been recognized all over the world when we come together to support people living with epilepsy. More than 300,000 Canadians are living with epilepsy and over 15,000 people learn each year that they have it. It is believed that the number of Canadians living with this disorder is even higher, but due to prejudice and stigma, many people are reluctant to seek treatment.

Petitions  Mr. Speaker, I rise to present a petition from students at the University of Victoria calling on the House to reject Bill C-51, the so-called anti-terrorism bill of 2015. Students call on all members to join with the NDP caucus in voting down this deeply flawed legislation. The students are not alone.

Canada Revenue Agency  Mr. Speaker, a report published today by the Environmental Law Centre of the University of Victoria raises very troubling questions about the so-called political activities audits being undertaken by the Canada Revenue Agency. It analyzes the alarming lack of clarity in the rules governing political activities for charities.

Canada Revenue Agency  Mr. Speaker, the credibility of the Canada Revenue Agency is at stake. The Conservatives are spending $13.4 million of taxpayers' money to target charities the Conservatives do not like at the same time as they are cutting $200 million from the overall budget of the CRA. It is very troubling.

Business of Supply  Mr. Speaker, that is why I opened my speech with a reference to plankton. Plankton may seem a long way from orcas, but of course, it is not. If the little creatures that are plankton are finding themselves ingesting microbeads and are unable to survive, and invertebrates that perhaps eat them are also ingesting slightly larger microplastics, and they cannot survive, it does not take a scientist to understand that the species at the top of the ladder will have difficulty with survival.

Business of Supply  Mr. Speaker, phosphates are one example of products that can be dealt with by both the federal and provincial governments, to some degree. Of course, most environmental water contaminants go across borders. My friend would be aware of that in the context of the Manitoba-Ontario border and the Saskatchewan-Manitoba border.

Business of Supply  Mr. Speaker, it is truly an honour to rise and speak to this motion that is so important to the people whom I represent. On an island in the Pacific, we are increasingly inundated with microplastics. Microbeads are a problem that could be regulated if the government had any interest in showing the leadership available to it under the Canadian Environmental Protection Act, 1999.

Business of Supply  Mr. Speaker, I listened with great interest to the presentation on this important issue by my colleague across the way. During questions and answers earlier today, the Parliamentary Secretary to the Minister of the Environment talked about this being dealt with through some sort of federal-provincial meeting that might take place this summer.

Questions Passed as Orders for Returns  With regard to Health Canada and the regulation of pharmaceutical manufacturing companies for the last ten years: (a) how many companies inspected in Canada have received a “proposal to suspend” letter, broken down by year; (b) how many companies inspected in Canada have received an “immediate suspension,” broken down by year; (c) how many companies inspected in Canada that were not sent a “proposal to suspend” letter or subject to a suspension has Health Canada worked with following an inspection to bring about compliance, broken down by year; (d) how many companies inspected in Canada have been subject to a re-inspection within six months, broken down by year; (e) how many companies inspected internationally have received a “proposal to suspend” letter, broken down by year; (f) how many companies inspected internationally have received an “immediate suspension,” broken down by year; (g) how many companies inspected internationally that were not sent a proposal to suspend letter or subject to a suspension has Health Canada worked with following an inspection to bring about compliance, broken down by year; (h) how many pharmaceutical manufacturing companies inspected internationally have been subject to a re-inspection within six months, broken down by year; (i) how many Import Alerts has Health Canada issued with regard to non-compliant health products, broken down by year; (j) which companies have been subject to an Import Alert; (k) how many voluntary quarantine requests has Health Canada issued, broken down by year; (l) which companies have been subject to a voluntary quarantine request; (m) how many “Notice of Intent to Suspend” letters have been issued to clinical trials, broken down by year; (n) how many “immediate suspensions” has Health Canada issued to clinical trials, broken down by year; (o) how many complaints have been received regarding off-label prescriptions of drugs, broken down by year; and (p) how many cases has Health Canada referred to the Public Prosecution Service of Canada for off-label prescriptions of drugs?

National Strategy for Dementia Act  Mr. Speaker, I must start by acknowledging the enormous amount of work that my college from Nickel Belt has done on such an important initiative. It has been three and a half years since this initiative first came forward. He has been all around the country. He has heard, not from statistics, but from real Canadians who are living with Alzheimer's and dementia and the tragedy that they entail, not just for the individuals, but for the caregivers.

National Strategy for Dementia Act  Mr. Speaker, I would like to congratulate the member for Nickel Belt, not only for his eloquence but for his personal courage in dealing with the crisis of which this bill speaks. For the House, I should also thank him for his patience. In that light, I wonder if the member might enlighten the House on the extent to which he may have had opportunity to work with the other parties in this House and the government.

Ethics  Mr. Speaker, this week we heard that the current Minister of Public Works passed over 160 proposals to fund one from a Conservative insider. What kind of message is the minister sending about the government? When a community organization applies for a grant to the Government of Canada, it should not feel the need to do favours for the Conservative Party.

Respect for Communities Act  Mr. Speaker, those are three questions, but I will try to be short in response to my hon. colleague. “Supervised injection site” is the right terminology. They are safe, however, because no one has died at Insite as a consequence of injecting there. BYOH is insulting. This is not what I want.

Respect for Communities Act  Mr. Speaker, I thank my hon. colleague for all her efforts on health reform in Canada. I much appreciate her comments. Why this bill was sent to the public safety committee rather than the health committee is simple. It is because the government does not see this as a health issue.